Send to

Choose Destination
Open Med (Wars). 2018 Oct 4;13:443-449. doi: 10.1515/med-2018-0066. eCollection 2018.

High Expression of NLRC5 Is Associated with Prognosis of Gastric Cancer.

Author information

School of Basic Medical Sciences of Pingdingshan University, Pingdingshan, Henan Province 467000, China.
Department of Pathology, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province 450014 China.
School of Basic Medical Sciences of Pingdingshan University, Pingdingshan, Chongwen Middle Road, Xinhua District, Pingdingshan City, Henan Province 467000, China.



To explore the relationships of NLRC5 with clinicopathological characteristics and prognosis of gastric cancer patients.


A total of 97 gastric cancer patients undergoing radical gastrectomy were enrolled. All patients were diagnosed by immunohistochemical staining. The relationship between NLRC5 expression and clinicopatho-logical characteristics of gastric cancer was analyzed via univariate and multivariate Cox regressions.


NLRC5 expression was positive in 70 cases (72.2%) and negative in 27 cases (27.8%). No significant differences in age, sex, or tumor size or differentiation were found between the negative and positive groups. NLRC5 expression was related to tumor site, and in the positive group, it was high in the fundus and low in the pylorus (χ2=7.359, P=0.125). NLRC5 expression was significantly related to lymph nodes and tumor node metastasis (TNM) staging (χ2=6.295; χ2=6.268). Multivariate Cox regression indicated positive NLRC5 expression was independently and significantly associated with prognosis of gastric cancer patients (HR=2.92, 95%CI: 1.51-5.63).


NLRC5 is closely related to TNM staging and lymph node metastasis of gastric cancer and is an independent risk factor for the prognosis of gastric cancer patients.


Clinicopathological characteristics; Gastric cancer; NLRC5; Prognosis

Conflict of interest statement

Conflict of interest Conflict of interests: The authors declare that they have no competing or any commercial or proprietary interest in any drug, device, or equipment mentioned in the submitted article.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center